BGIM
CPRX

Brandywine Global Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Brandywine Global Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$7M Sell
300,116
-10,874
-3% -$242K 0.05% 318
2025
Q3 		$6.13M Buy
+310,990
New +$6.4M 0.04% 346
2024
Q4 		– Sell
-392,118
Closed -$8.09M – 595
2024
Q3 		$8.09M Sell
392,118
-43,513
-10% -$807K 0.05% 308
2024
Q2 		$6.75M Buy
435,631
+64,248
+17% +$1M 0.05% 339
2024
Q1 		$5.92M Buy
371,383
+192,853
+108% +$2.91M 0.04% 379
2023
Q4 		$3M Sell
178,530
-38,679
-18% -$529K 0.02% 489
2023
Q3 		$2.54M Buy
217,209
+4,700
+2% +$62.9K 0.02% 508
2023
Q2 		$2.86M Sell
212,509
-1,000
-0.5% -$14.4K 0.02% 490
2023
Q1 		$3.54M Hold
213,509
– – 0.03% 465
2022
Q4 		$3.97M Hold
213,509
– – 0.03% 438
2022
Q3 		$2.74M Sell
213,509
-8,758
-4% -$104K 0.03% 476
2022
Q2 		$1.56M Sell
222,267
-32,400
-13% -$238K 0.01% 568
2022
Q1 		$2.11M Hold
254,667
– – 0.02% 535
2021
Q4 		$1.72M Sell
254,667
-96,975
-28% -$638K 0.01% 544
2021
Q3 		$1.86M Buy
351,642
+2,014
+0.6% +$11K 0.01% 534
2021
Q2 		$2.01M Sell
349,628
-4,259
-1% -$22K 0.01% 536
2021
Q1 		$1.63M Sell
353,887
-3,438
-1% -$13.7K 0.01% 541
2020
Q4 		$1.19M Sell
357,325
-92,355
-21% -$310K 0.01% 522
2020
Q3 		$1.34M Buy
449,680
+108,890
+32% +$426K 0.01% 491
2020
Q2 		$1.57M Buy
340,790
+3,228
+1% +$14.5K 0.02% 477
2020
Q1 		$1.3M Buy
337,562
+2,150
+0.6% +$8.82K 0.02% 493
2019
Q4 		$1.26M Buy
335,412
+53,735
+19% +$251K 0.01% 557
2019
Q3 		$1.5M Sell
281,677
-67,395
-19% -$359K 0.01% 555
2019
Q2 		$1.34M Buy
349,072
+135,597
+64% +$586K 0.01% 568
2019
Q1 		$1.09M Buy
+213,475
New +$628K 0.01% 539

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brandywine Global Investment Management's CPRX Position: Q4 2025 in Review

Brandywine Global Investment Management reduced its Catalyst Pharmaceutical (CPRX) stake by 3.5% in Q4 2025, selling an estimated $242K and leaving 300,116 shares worth $7M. The position accounts for 0.05% of the portfolio, ranked #318.

Brandywine Global Investment Management first reported a position in CPRX in Q1 2019 and has held it in 25 quarters since. The position peaked at $8.09M in Q3 2024. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Brandywine Global Investment Management held 300,116 shares of Catalyst Pharmaceutical worth $7M as of Q4 2025.
  • Brandywine Global Investment Management sold 10,874 Catalyst Pharmaceutical shares in Q4 2025, an estimated $242K.
  • Catalyst Pharmaceutical made up 0.05% of Brandywine Global Investment Management's portfolio in Q4 2025, its #318 holding.
  • Brandywine Global Investment Management first reported a position in Catalyst Pharmaceutical in Q1 2019 and has held it in 25 quarters since.
  • Brandywine Global Investment Management's Catalyst Pharmaceutical position peaked at $8.09M in Q3 2024.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Brandywine Global Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.